Drug Type Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals |
Synonyms 177Lu-RAYZ 6283, 177Lu-RAYZ6283 |
Target |
Mechanism EphA2 antagonists(Ephrin type-A receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Preclinical | US | 25 May 2023 | |
Prostatic Cancer | Preclinical | JP | Rayzebio, Inc.Startup | 25 May 2023 |